Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29529257 | 0.93 | ADORA3 (0.44) | TYMPADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL24512768 | 0.93 | ADORA3 (0.44) | TYMPADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1097143 | 0.93 | ADORA3 (0.44) | TYMPADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL19814055 | 0.93 | ADORA3 (0.44) | TYMPADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL31390282 | 0.88 | TYMP (0.42) | TYMPADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL22594746 | 0.88 | ADORA3 (0.43) | TYMPADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL25630100 | 0.86 | TYMP (0.40) | TYMPADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL29610113 | 0.85 | ADORA3 (0.45) | TYMPADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL20394061 | 0.85 | ADORA3 (0.45) | TYMPADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL21750447 | 0.85 | TYMP (0.39) | TYMPADORA2BADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1152009-B2 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | claimed |
| US-20230348522-A1 | METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-11-02 | — | — | US | disclosed |
| EP-1152009-B2 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-1152009-B1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | SANKYO CO (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348522-A1 | METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE | PFAS, ENPP1, NAAA | TYMP 113/4885ADORA2B 2249/4885ADORA2A 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.